The impact of pharmacokinetic gene profiles across human cancers

[1] Bielinski SJ(2014)Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol Mayo Clin Proc 89 25-33

[2] Olson JE(2016)Clinical implementation of integrated genomic profiling in patients with advanced cancers Sci Rep 6 25-23

[3] Pathak J(2014)Implementing individualized medicine into the medical practice Am J Med Genet C Semin Med Genet 166C 15-622

[4] Weinshilboum RM(2014)Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel Oncologist 19 616-612

[5] Wang L(2012)The role of mutations in epigenetic regulators in myeloid malignancies Nat Rev Cancer 12 599-1672

[6] Lyke KJ(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1684

[7] Ryu E(2005)Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673-54

[8] Targonski PV(2008)Public health. A case study of personalized medicine Science 320 53-730

[9] Van Norstrand MD(2002)The druggable genome Nat Rev Drug Discov 1 727-1210

[10] Hathcock MA(2013)DGIdb: mining the druggable genome Nat Methods 10 1209-467

[1] Bielinski SJ(2014)Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol Mayo Clin Proc 89 25-33

[2] Olson JE(2016)Clinical implementation of integrated genomic profiling in patients with advanced cancers Sci Rep 6 25-23

[3] Pathak J(2014)Implementing individualized medicine into the medical practice Am J Med Genet C Semin Med Genet 166C 15-622

[4] Weinshilboum RM(2014)Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel Oncologist 19 616-612

[5] Wang L(2012)The role of mutations in epigenetic regulators in myeloid malignancies Nat Rev Cancer 12 599-1672

[6] Lyke KJ(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1684

[7] Ryu E(2005)Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673-54

[8] Targonski PV(2008)Public health. A case study of personalized medicine Science 320 53-730

[9] Van Norstrand MD(2002)The druggable genome Nat Rev Drug Discov 1 727-1210

[10] Hathcock MA(2013)DGIdb: mining the druggable genome Nat Methods 10 1209-467